Infliximab biosimilar only moderately less expensive in Medicare Part DSeptember 6, 2018Psoriatic ArthritisPsoriasis
Risankizumab proves more effective in psoriasis than ustekinumabAugust 28, 2018PsoriasisPsoriatic Arthritis
Psoriasis registry study provides more data on infliximab’s infection riskAugust 16, 2018PsoriasisPsoriatic Arthritis
FDA announces plan for biosimilar innovation and competitionJuly 19, 2018PsoriasisPsoriatic Arthritis
Elderly patients with psoriasis can benefit from biologics with low rates of adverse eventsJune 29, 2018Psoriatic ArthritisPsoriasis
Checkpoint inhibitors in autoimmune disease: More flares, better cancer outcomesJune 25, 2018Psoriatic Arthritis
Biologic efficacy differs in psoriatic arthritis by lymphocyte phenotypeJune 25, 2018Psoriatic Arthritis
EULAR scientific program highlights spectrum of translational researchJune 11, 2018Psoriatic Arthritis
